CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

36 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaALK Inhibitor TAE684George et al., 2008
BALKMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibShaw et al., 2014
CALKI1171PredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinibKatayama et al., 2014
CALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibKatayama et al., 2014
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaLorlatinibInfarinato et al., 2016
DALKR1275QPredictiveSupportsSensitivity/ResponseNeuroblastomaLorlatinibInfarinato et al., 2016
DALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibFriboulet et al., 2014
CALKAlternative Transcript (ATI)PredictiveSupportsSensitivity/ResponseSkin MelanomaCrizotinibWiesner et al., 2015
CALKAlternative Transcript (ATI)PredictiveDoes Not SupportSensitivity/ResponseMucosal MelanomaEntrectinibCouts et al., 2018
CALKI1171TPredictiveSupportsSensitivity/ResponseNeuroblastomaCeritinibGuan et al., 2018
DALKF1174LPredictiveSupportsResistanceInflammatory Myofibroblastic TumorCrizotinibSasaki et al., 2010
DALKF1174LPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibSasaki et al., 2010
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaAlectinibSakamoto et al., 2011
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaCrizotinibHeuckmann et al., 2011
DALKR1275QPredictiveSupportsResistanceNeuroblastomaALK Inhibitor TAE684George et al., 2008
DALKF1174LPredictiveSupportsResistanceNeuroblastomaCrizotinibBresler et al., 2011
DALKR1275QPredictiveSupportsSensitivity/ResponseNeuroblastomaCrizotinibBresler et al., 2011
CALKF1174LPredictiveDoes Not SupportSensitivity/ResponseNeuroblastomaCrizotinibMossé et al., 2013
DALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaALK Inhibitor TAE684Katayama et al., 2014
DALKI1171PredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKatayama et al., 2014
DALKF1174LPredictiveSupportsSensitivity/ResponseNeuroblastomaAZD3463Wang et al., 2016
DALKF1245CPredictiveSupportsSensitivity/ResponseNeuroblastomaLorlatinibInfarinato et al., 2016
CALKF1245CPredictiveSupportsResistanceNeuroblastomaCrizotinibMossé et al., 2013
DALKExon 4-11 DeletionPredictiveSupportsSensitivity/ResponseNeuroblastomaBrigatinibSiaw et al., 2016
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibFriboulet et al., 2014
DALKG1269A AND v::ALK FusionPredictiveSupportsResistanceCancerAlectinibFontana et al., 2015
CALKG1202R AND v::ALK FusionPredictiveSupportsResistanceLung AdenocarcinomaCrizotinibKatayama et al., 2012
CALKI1171PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCeritinibOu et al., 2015
CALKF1245VPredictiveSupportsSensitivity/ResponseNeuroblastomaEntrectinibDrilon et al., 2017
DALKR1275QPredictiveSupportsSensitivity/ResponseCancerALK Inhibitor TAE684George et al., 2008
CALKR1275QPredictiveSupportsSensitivity/ResponseNeuroblastomaCrizotinibMossé et al., 2013
CALKR1275QPredictiveSupportsSensitivity/ResponseNeuroblastomaCrizotinibMossé et al., 2013
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseCancerBrigatinibFontana et al., 2015
DALKG1269A AND v::ALK FusionPredictiveSupportsSensitivity/ResponseCancerCeritinibFontana et al., 2015
CALKI1171PredictiveSupportsResistanceLung Non-small Cell CarcinomaAlectinibOu et al., 2015
CALKI1171N AND HIP1::ALK FusionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinib,AlectinibOu et al., 2014